Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free
$35M0%Beat EPS +545.0%
Total revenue, Q2 '26 ().

Did Actinium Pharmaceuticals Beat Earnings?

Actinium Pharmaceuticals (ATNM) reported Q2 '26 revenue of $35M, with reported EPS of $0.89. That topped the $-0.20 analyst estimate by 545.0% — an earnings beat.

AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Actinium Pharmaceuticals’s job postings, web traffic, and employee business outlook. See the full ATNM stock analysis or the earnings calendar for upcoming reports.

Actinium Pharmaceuticals Quarterly Financial Trends ()

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Revenue—810,000——90,000——35M
Gross margin—-25.2%——100.0%——100.0%
Operating margin—-926.5%——-6,324.4%——78.8%
Net income-12M-6.7M-16M-6.9M-5.1M-5.9M-5.5M28M
Net margin—-821.2%——-5,701.1%——79.7%
EPS———————$0.89

Actinium Pharmaceuticals Earnings Trend Analysis

Over the eight quarters from Q3 '24 to Q2 '26, Actinium Pharmaceuticals’s quarterly revenue moved from $0 to $35M. Actinium Pharmaceuticals has beaten Wall Street EPS estimates in 1 of its last 1 reported quarters.

When Is Actinium Pharmaceuticals’s Next Earnings Date?

Actinium Pharmaceuticals reports earnings on a quarterly schedule. Its most recent report covered Q2 '26. For the confirmed upcoming date — and every other company reporting soon — see the ATNM earnings calendar.

Frequently Asked Questions: Actinium Pharmaceuticals Earnings

Actinium Pharmaceuticals's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.

Actinium Pharmaceuticals reported Q2 '26 EPS of $0.89 on revenue of $35M. Actinium Pharmaceuticals beat estimates, reporting $0.89 vs. the $-0.20 estimate.

Actinium Pharmaceuticals reported Q2 '26 revenue of $35M.

Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the ATNM AI Score.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.